FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016201212> ?p ?o ?g. }

• W3016201212 endingPage "e69" @default.
• W3016201212 startingPage "e56" @default.
• W3016201212 abstract "Background: This document provides clinical recommendations for the pharmacologic treatment of chronic obstructive pulmonary disease (COPD). It represents a collaborative effort on the part of a panel of expert COPD clinicians and researchers along with a team of methodologists under the guidance of the American Thoracic Society.Methods: Comprehensive evidence syntheses were performed on all relevant studies that addressed the clinical questions and critical patient-centered outcomes agreed upon by the panel of experts. The evidence was appraised, rated, and graded, and recommendations were formulated using the Grading of Recommendations, Assessment, Development, and Evaluation approach.Results: After weighing the quality of evidence and balancing the desirable and undesirable effects, the guideline panel made the following recommendations: 1) a strong recommendation for the use of long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) combination therapy over LABA or LAMA monotherapy in patients with COPD and dyspnea or exercise intolerance; 2) a conditional recommendation for the use of triple therapy with inhaled corticosteroids (ICS)/LABA/LAMA over dual therapy with LABA/LAMA in patients with COPD and dyspnea or exercise intolerance who have experienced one or more exacerbations in the past year; 3) a conditional recommendation for ICS withdrawal for patients with COPD receiving triple therapy (ICS/LABA/LAMA) if the patient has had no exacerbations in the past year; 4) no recommendation for or against ICS as an additive therapy to long-acting bronchodilators in patients with COPD and blood eosinophilia, except for those patients with a history of one or more exacerbations in the past year requiring antibiotics or oral steroids or hospitalization, for whom ICS is conditionally recommended as an additive therapy; 5) a conditional recommendation against the use of maintenance oral corticosteroids in patients with COPD and a history of severe and frequent exacerbations; and 6) a conditional recommendation for opioid-based therapy in patients with COPD who experience advanced refractory dyspnea despite otherwise optimal therapy.Conclusions: The task force made recommendations regarding the pharmacologic treatment of COPD based on currently available evidence. Additional research in populations that are underrepresented in clinical trials is needed, including studies in patients with COPD 80 years of age and older, those with multiple chronic health conditions, and those with a codiagnosis of COPD and asthma." @default.
• W3016201212 created "2020-04-17" @default.
• W3016201212 creator A5002250762 @default.
• W3016201212 creator A5004128310 @default.
• W3016201212 creator A5009003396 @default.
• W3016201212 creator A5016784895 @default.
• W3016201212 creator A5018274823 @default.
• W3016201212 creator A5026096786 @default.
• W3016201212 creator A5028571055 @default.
• W3016201212 creator A5042188739 @default.
• W3016201212 creator A5047081228 @default.
• W3016201212 creator A5050241854 @default.
• W3016201212 creator A5054105827 @default.
• W3016201212 creator A5055605251 @default.
• W3016201212 creator A5059018267 @default.
• W3016201212 creator A5060850749 @default.
• W3016201212 creator A5064775862 @default.
• W3016201212 creator A5065133242 @default.
• W3016201212 creator A5067072009 @default.
• W3016201212 creator A5067232021 @default.
• W3016201212 creator A5072981488 @default.
• W3016201212 creator A5073082660 @default.
• W3016201212 creator A5082568705 @default.
• W3016201212 creator A5083315765 @default.
• W3016201212 creator A5091415199 @default.
• W3016201212 date "2020-05-01" @default.
• W3016201212 modified "2023-10-11" @default.
• W3016201212 title "Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline" @default.
• W3016201212 cites W1950043623 @default.
• W3016201212 cites W1977733462 @default.
• W3016201212 cites W1980789906 @default.
• W3016201212 cites W1982291590 @default.
• W3016201212 cites W1987881697 @default.
• W3016201212 cites W1999132346 @default.
• W3016201212 cites W1999413617 @default.
• W3016201212 cites W2001504037 @default.
• W3016201212 cites W2006528231 @default.
• W3016201212 cites W2026247098 @default.
• W3016201212 cites W2026585673 @default.
• W3016201212 cites W2030113969 @default.
• W3016201212 cites W2039237831 @default.
• W3016201212 cites W2052087538 @default.
• W3016201212 cites W2056040906 @default.
• W3016201212 cites W2065887540 @default.
• W3016201212 cites W2066887427 @default.
• W3016201212 cites W2067661817 @default.
• W3016201212 cites W2072962612 @default.
• W3016201212 cites W2075195662 @default.
• W3016201212 cites W2086342579 @default.
• W3016201212 cites W2101978351 @default.
• W3016201212 cites W2104636056 @default.
• W3016201212 cites W2104898680 @default.
• W3016201212 cites W2105234929 @default.
• W3016201212 cites W2108580199 @default.
• W3016201212 cites W2111871885 @default.
• W3016201212 cites W2123850585 @default.
• W3016201212 cites W2128278745 @default.
• W3016201212 cites W2128643475 @default.
• W3016201212 cites W2142449488 @default.
• W3016201212 cites W2145316343 @default.
• W3016201212 cites W2146831425 @default.
• W3016201212 cites W2157851934 @default.
• W3016201212 cites W2162672497 @default.
• W3016201212 cites W2165909321 @default.
• W3016201212 cites W2166424804 @default.
• W3016201212 cites W2167795093 @default.
• W3016201212 cites W2172490363 @default.
• W3016201212 cites W2318340572 @default.
• W3016201212 cites W2324038222 @default.
• W3016201212 cites W2329158407 @default.
• W3016201212 cites W2345974479 @default.
• W3016201212 cites W2520342023 @default.
• W3016201212 cites W2558903543 @default.
• W3016201212 cites W2588781854 @default.
• W3016201212 cites W2591678263 @default.
• W3016201212 cites W2593670800 @default.
• W3016201212 cites W2594397173 @default.
• W3016201212 cites W2604743750 @default.
• W3016201212 cites W2785999277 @default.
• W3016201212 cites W2794699839 @default.
• W3016201212 cites W2802221596 @default.
• W3016201212 cites W2804974357 @default.
• W3016201212 cites W2891482814 @default.
• W3016201212 cites W2892770417 @default.
• W3016201212 cites W2955793705 @default.
• W3016201212 cites W2955803684 @default.
• W3016201212 doi "https://doi.org/10.1164/rccm.202003-0625st" @default.
• W3016201212 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7193862" @default.
• W3016201212 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32283960" @default.
• W3016201212 hasPublicationYear "2020" @default.
• W3016201212 type Work @default.
• W3016201212 sameAs 3016201212 @default.
• W3016201212 citedByCount "177" @default.
• W3016201212 countsByYear W30162012122020 @default.
• W3016201212 countsByYear W30162012122021 @default.
• W3016201212 countsByYear W30162012122022 @default.
• W3016201212 countsByYear W30162012122023 @default.
• W3016201212 crossrefType "journal-article" @default.

• next